Clinical Trials Sponsored by Swiss Center for Musculoskeletal Imaging

Total 355 results

Philipp Fürnstahl
KU Leuven; Swiss Center for Musculoskeletal Imaging

Completed

Robot-Assisted US-Based Vertebral Segmentation for Pedicle Screw Trajectory Identification

Healthy

Switzerland
Center for Diagnostic Imaging

Unknown

Evaluation of Stool Tagging for Improved Patient Compliance

Polyps | Colon Cancer

United States
Swiss Group for Clinical Cancer Research

Recruiting

Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

Bladder Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Recruiting

Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.

Diffuse Large B-cell Lymphoma

Switzerland, Italy
Swiss Group for Clinical Cancer Research

Recruiting

Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)

NSCLC | Non-small Cell Lung Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Recruiting

TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors

Advanced Solid Tumors

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)

NSCLC Non-small Cell Lung Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Active, not recruiting

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

Metastatic Breast Cancer | Bone Metastases | Metastatic Prostate Cancer

Switzerland, Germany, Austria
Swiss Group for Clinical Cancer Research

Active, not recruiting

Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC

Metastatic Castration-resistant Prostate Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Terminated

Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone

Prostate Cancer | Cancer of the Prostate

Switzerland
Swiss Group for Clinical Cancer Research

Terminated

CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer

Breast Cancer | Metastatic Breast Adenocarcinoma

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Activity Program During Aromatase Inhibitor Therapy

Early Breast Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Terminated

Extended Pelvic Lymph Node Dissection vs. no Pelvic Lymph Node Dissection at Radical Prostatectomy for intermediate-and High-risk Prostate Cancer

Prostate Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Terminated

Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer (RECAP)

Rectal Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Terminated

Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line Chemotherapy

Metastatic Colorectal Cancer

Switzerland, Austria
Swiss Group for Clinical Cancer Research

Completed

Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC)

Lung Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.

Malignant Pleural Mesothelioma, Advanced

Switzerland, Italy
Swiss Group for Clinical Cancer Research

Completed

Trastuzumab & Pertuzumab Followed by T-DM1 in MBC

Metastatic Breast Cancer

France, Switzerland, Netherlands, Germany
Swiss Group for Clinical Cancer Research

Terminated

Bevacizumab in Treating Patients Who Have Undergone First-Line Therapy for Metastatic Colorectal Cancer

Colorectal Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Vinorelbine in Treating Patients With Metastatic Prostate Cancer

Prostate Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy

Breast Cancer

Switzerland, Belgium
Swiss Group for Clinical Cancer Research

Completed

Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC

Lung Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy

Prostate Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Terminated

Cetuximab for Elderly Patients With mCRC

Metastatic Colorectal Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Terminated

Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer

Liver Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Capecitabine and Radiation Therapy With or Without Panitumumab in Treating Patients With Advanced Rectal Cancer

Colorectal Cancer

Switzerland, Hungary
Swiss Group for Clinical Cancer Research

Completed

Azacitidine in Treating Patients With Newly Diagnosed Previously Untreated or Secondary Acute Myeloid Leukemia Who Are Unsuitable For Intensive Chemotherapy

Leukemia

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases

Lung Cancer | Metastatic Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Capecitabine and Oxaliplatin With or Without Cetuximab in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery

Colorectal Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma

Lymphoma

Italy, Switzerland, Austria, Germany, Greece
Swiss Group for Clinical Cancer Research

Completed

Rituximab in Treating Patients With Refractory or Recurrent Hairy Cell Leukemia Following Cladribine Therapy

Leukemia

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia

Leukemia

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Paclitaxel in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia

Leukemia

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Combination Chemotherapy in Treating Patients With Advanced or Metastatic Colorectal Cancer

Colorectal Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Not yet recruiting

Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

Triple-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Recruiting

LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma (SAKK 38/23)

Non-hodgkin Lymphoma, B Cell

Switzerland
Swiss Group for Clinical Cancer Research

Active, not recruiting

Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL

Leukemia | Chronic Lymphocytic Leukemia | Relapsed/Refractory Chronic Lymphocytic Leukemia

Switzerland
Swiss Group for Clinical Cancer Research

Terminated

ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.

Prostate Cancer | Prostate Cancer Metastatic

France, Switzerland, Spain, Italy
Swiss Group for Clinical Cancer Research

Completed

Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients

Lung Cancer

Germany, Serbia, Switzerland
Swiss Group for Clinical Cancer Research

Active, not recruiting

1st Line Durvalumab in PS 2 NSCLC Patients

NSCLC Stage IV | NSCLC Stage IIIB

Switzerland
Swiss Group for Clinical Cancer Research

Active, not recruiting

Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).

Small Cell Lung Cancer | Lung Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Active, not recruiting

Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer. (SAKK 06/17)

Urothelial Cancer

Germany, Switzerland
Swiss Group for Clinical Cancer Research

Terminated

Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)

Squamous-cell Non-small Cell Lung Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Terminated

Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer

Adenocarcinoma | Breast Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.

Lung Cancer | KRAS Gene Mutation | Advanced Non-small Cell Lung Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Terminated

Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma (OptiPOM)

Refractory Multiple Myeloma

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Metformin Hydrochloride as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Prostate Cancer

Prostate Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Everolimus as First-Line Therapy in Treating Patients With Prostate Cancer

Prostate Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Biological Therapy in Treating Patients With Bladder Cancer

Bladder Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumor

France, Switzerland, Germany, Finland

Clinical Trials Sponsored by Swiss Center for Musculoskeletal Imaging

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations